Genmab and Janssen have announced that the US Food and Drug Administration (FDA) has expanded the approval of daratumumab (Darzalex®) as part of a treatment combination for relapsed and/or refractory myeloma patients. Currently licensed by the FDA for use as a monotherapy for patients who have received at least three previous treatments or in combination with lenalidomide (Revlimid®) or bortezomib (Velcade®) and dexamethasone for patients who have received at least one previous treatment, the latest approval allows for the use of daratumumab in combination with pomalidomide (Imnovid®) and dexamethasone for patients who have received at least two prior lines of treatments including lenalidomide and a proteasome inhibitor.

 

Read article